

Synthesis and antitumor mechanism of a copper(II) complex of anthracene-9-imidazoline hydrazone (9-AIH)

Qi-Pin Qin, Yan-Cheng Liu*, Hai-Lu Wang, Jiao-Lan Qin, Feng-Jie Cheng, Shang-Feng Tang,
and Hong Liang*

State Key Laboratory Cultivation Base for the Chemistry and Molecular Engineering of Medicinal Resources; School of Chemistry & Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, P. R. China.

Table S1. Selected bond lengths (Å) and bond angles (°) for the complex **1**.

bond lengths (Å)		bond angles (°)	
Cu(1)–O(1)	1.902(2)	O(1)– Cu(1)–O(2)	89.61(9)
Cu(1)–N(1)	1.967(2)	O(1)– Cu(1)–O(3)	90.29(9)
Cu(1)–O(2)	1.993(2)	O(1)– Cu(1)–N(1)	93.73(9)
Cu(1)–O(3)	2.322(2)	O(1)– Cu(1)–N(2)	173.51(9)
Cu(1)–N(2)	1.978(2)	O(2)– Cu(1)–O(3)	88.58(9)
Cu(2)–O(6)	1.896(19)	N(1)– Cu(1)–O(2)	168.43(9)
Cu(2)–O(7)	1.972(2)	N(1)– Cu(1)–O(3)	102.47(10)
Cu(2)–N(4)	1.963(2)	N(1)– Cu(1)–N(2)	83.16(9)
Cu(2)–N(5)	1.971(2)	N(2)– Cu(1)–O(2)	92.37(9)
Cu(2)–O(8)	2.413(3)	N(2)– Cu(1)–O(3)	95.93(9)

Table S2. The inhibitive ratios of complex **1** and 9-AIH against five selected tumor cell lines and one normal liver cell line HL-7702 for 48 h.

Compounds	Inhibition ratios (% , uniformly at 20 µM)					
	BEL-7404	HepG2	MGC80-3	NCI-H460	HeLa	HL-7702
9-AIH ^a	80.08±0.57	76.36±0.59	83.91±2.05	71.55±1.94	81.69±0.63	56.10±0.09
Complex 1 ^a	97.23±0.12	88.12±0.41	90.49±0.85	84.62±0.79	83.10±0.62	85.50±0.83
CuCl ₂ •2H ₂ O ^b	15.44±1.02	16.33±0.94	10.25±0.78	8.05±0.76	12.84±1.52	11.65±1.01
Cisplatin ^c	65.15±1.08	60.63±0.99	71.35±1.46	61.85±1.69	80.56±0.92	73.58±2.30

Results represent mean ± SD of at least five independent experiments. SD represents the standard deviation. ^a The concentration is 2 × 10⁻⁵ mol/L. ^b The concentration is 1 × 10⁻⁴ mol/L. ^c Cisplatin was dissolved at a concentration of 1 mM in 0.154 M NaCl.




Figure S1. The stacking presentation of complex **1** viewed from the *c*-axis showing the N—H···Cl and C—H···Cl hydrogen bonding and π – π stacking between the neighboring anthracene groups.




Figure S2. UV-vis spectrum of complex **1** in tris buffer solution (containing 5% DMSO) for 0 h

(dashed line) and for 24 h (solid line), respectively.





Figure S3. The time-dependent HPLC spectra for complex **1** (6.0×10^{-3} M stock solution in DMSO) with 0 h and 24 h. Column: Inertsustain C18 column (LC-20AT, SPD-20A HPLC Column, 150mm $\times$ 5.0 μ m I. D.). Column temperature: 40°C. Mobile phase: methanol/H₂O containing 0.01% TFA (85/15 as methanol/H₂O). Flow rate: 1.0 mL/min. Injection volume: 3.0×10^{-4} M.



Acquisition Parameter					
Ion Source Type	ESI	Ion Polarity	Positive	Alternating Ion Polarity	off
Mass Range Mode	Ultra Scan	Scan Begin	300 m/z	Scan End	800 m/z
Capillary Exit	98.5 Volt	Skimmer	40.0 Volt	Trap Drive	90.3
Accumulation Time	3721 μ s	Averages	5 Spectra	Auto MS/MS	off




Figure S4. The mass spectra of complex **1** in tris buffer solution (containing 5% DMSO) for 0 h (top) and 24 h (down), respectively.




Figure S5. The significant cell apoptosis in BEL-7404 cells induced by 20 μ M of 9-AIH and complex **1** for 24 h, respectively, which clearly showed that the apoptotic BEL-7404 cells in the late stage was predominant under the incubation of both compounds in such a high concentration.




Figure S6. The expression level of caspase-9 and caspase-3 pro-apoptotic protein enhanced in BEL-7404 cells under the treatment of complex **1** and 9-AIH at 1.0 μ M for 12 h. Caspase-3 was assessed using the CasPGLOW™ Fluorescein Activite Caspase-3 Staining kit by flow cytometry.